Epidemiology, Diagnostics and Therapy of Vulvovaginal Fungal Infections.

Magdalena Frej-Mądrzak, Agnieszka Jama-Kmiecik, Aleksandra Górzyńska, Nikola Wahdan, Urszula Nawrot

Abstract readReview

In one paragraph

Review in Pathogens (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Magdalena Frej-MądrzakDepartment of Microbiology, Faculty of Medicine, Wroclaw Medical University, Chalubińskiego 4, 50-368 Wroclaw, Poland.

Agnieszka Jama-KmiecikDivision of Medical Biology, Faculty of Nursing and Midwifery, Wroclaw Medical University, Chalubińskiego 4, 50-368 Wroclaw, Poland.

Aleksandra GórzyńskaDepartment of Pharmaceutical Microbiology and Parasitology, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211a, 50-556 Wroclaw, Poland.

Nikola WahdanDepartment of Pharmaceutical Microbiology and Parasitology, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211a, 50-556 Wroclaw, Poland.

Urszula NawrotDepartment of Pharmaceutical Microbiology and Parasitology, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211a, 50-556 Wroclaw, Poland.ORCID 0000-0002-0906-2377

Funding

Wroclaw Medical University SUBZ.D230.26.016

6 · The paper itself

Abstract

Vulvovaginal candidiasis (VVC) is one of the most common superficial fungal infections affecting women. A particularly challenging issue is the treatment of recurrent vulvovaginal candidiasis (RVVC)-defined as ≥4 episodes of VVC within 12 months-which affects 5-8% of women with VVC. The development of VVC is influenced by many risk factors related to the host organism and behaviour, including disturbances in the vaginal microflora, hormonal fluctuations, diabetes, hygiene and sexual behaviour. Although

Indexed as

Antifungal AgentsCandidiasis, VulvovaginalDrug Resistance, FungalFemaleHumansMicrobial Sensitivity TestsRisk FactorsAntifungal AgentsCandida albicansepidemiologyvulvovaginal candidiasisVVC

Identifiers

PMID42796682

DOI10.3390/pathogens15090914

PMCPMC13610137

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.